Navigation Links
NCCN Receives $4 Million Oncology Research Grant from Wyeth
Date:1/15/2009

NCCN recently received a $4 million research grant from Wyeth Pharmaceuticals to evaluate the safety and effectiveness of temsirolimus in the treatment of solid tumors. Temsirolimus is currently approved to treat advanced renal cell carcinoma (RCC). This grant is the largest research award received by NCCN to date. Investigators from NCCN Member Institutions are eligible to apply for the research funding.

FORT WASHINGTON, Pa., Jan. 15 /PRNewswire-USNewswire/ -- The National Comprehensive Cancer Network (NCCN) has been awarded a $4 million grant from Wyeth Pharmaceuticals to support clinical studies of temsirolimus (Torisel(R), Wyeth) in the treatment of solid tumors. This is the largest individual research grant that NCCN has received since the inception of its Oncology Research Program in 1999.

Temsirolimus is a targeted therapy approved to treat advanced renal cell carcinoma (RCC), a type of cancer that originates in the kidney. Clinical trials supported by this grant will evaluate the effectiveness of temsirolimus in solid tumors, including but not limited to, breast, endometrial, head and neck, hepatocellular, hormone-refractory prostate, non-small cell lung, and ovarian cancers.

"This grant represents the largest research award to date for NCCN and is an outstanding achievement," says William T. McGivney, PhD, Chief Executive Officer, NCCN. "The funding not only helps accelerate potentially life-saving research in the field of cancer, but also creates a collaborative opportunity for investigators from NCCN Member Institutions. Obtaining major research grants represents yet another way in which NCCN lives out our mission of improving the quality and effectiveness of care provided to patients with cancer."

Temsirolimus is the only commercially available inhibitor of mammalian target of rapamycin (mTOR). The mTOR signaling pathway regulates cell growth and promotes angiogenesis, a physiological process that is a fundamental step in the transition of tumors from a dormant state to a malignant state. By disrupting this pathway, temsirolimus may inhibit the growth of tumors.

"This collaboration represents a unique opportunity to benefit from the research expertise of NCCN and their Member Institutions as we explore the potential of Torisel in the treatment of a variety of solid tumors," says Mikael Dolsten, President, Research and Development, Wyeth Pharmaceuticals. "We are pleased to support an organization that shares our commitment to innovative cancer research to the benefit of patients with cancer."

The primary goal of clinical trials resulting from this grant is to help determine the role of temsirolimus in the treatment of solid tumors in a variety of cancers. Significant secondary goals include:

  • Identification of cancers or cancer subtypes that may be dependent on the mTOR pathway.
  • Clarification of the mechanism of action of mTOR inhibition in different tumors.
  • Investigation of combination therapy with cytotoxics, targeted therapies, biologic agents, and radiation therapy, based on hypothesis generating preclinical studies.
  • Identification of biomarkers and molecular imaging that can be used to assess mTOR inhibition.

The NCCN Oncology Research Program (ORP) facilitates all phases of clinical research by identifying clinical investigators and initiating trials at NCCN Member Institutions. The ORP draws on the expertise of investigators at 21 of the world's leading cancer centers and establishes collaborations with pharmaceutical and biotech companies in order to advance therapeutic options for patients with cancer.

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.

The NCCN Member Institutions are: City of Hope, Los Angeles, CA; Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Comprehensive Cancer Center, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; Arthur G. James Cancer Hospital & Richard J. Solove Research Institute at The Ohio State University, Columbus, OH; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children's Research Hospital/University of Tennessee Cancer Institute, Memphis, TN; Stanford Comprehensive Cancer Center, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; UNMC Eppley Cancer Center at The Nebraska Medical Center, Omaha, NE; The University of Texas M. D. Anderson Cancer Center, Houston, TX; and Vanderbilt-Ingram Cancer Center, Nashville, TN.

For more information on NCCN, please visit www.nccn.org.


'/>"/>
SOURCE National Comprehensive Cancer Network
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
2. DaVita Receives Civil Complaint
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
4. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
5. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
6. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
7. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
8. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
9. Prime Therapeutics Receives TIPPS Certification
10. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
11. UCLA receives $22.5 million to explore the fundamental biology of mental disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... Beleza Medspa ... fat composition regulations. This is the first time that Coolsculpting is being used ... least every six months to ensure they meet the prescribed body-fat standard, measured by ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... Despite last ... meeting, expect Janet Yellen and company to wait until March 2017 for an interest ... University’s J. Mack Robinson College of Business. , “The Federal Open Market Committee (FOMC) ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... property (IP) to its specialty academic programs. , Answering to the increasing demand ... certificate programs in health law, and environmental and land use law. ,  , ...
(Date:5/26/2016)... , ... May 26, 2016 , ... There are nearly ... than 32 million cancer survivors worldwide. On Sunday, June 5, 2016, communities around the ... National Cancer Survivors Day®. , National Cancer Survivors Day® is an annual worldwide ...
(Date:5/26/2016)... , ... May 26, 2016 , ... In an effort to provide hair restoration information ... both Snapchat users and those who do not use the app. Dr. Mohebi, the founder ... page, Dr. Mohebi Live . , Dr. Mohebi says, “The positive response to ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... , May 24, 2016 Cirujanos ... para ayudar a los médicos a compartir sus mejores ... a escala mundial. Profesionales médicos de Europa, África, ... han apuntado a la aplicación, que combina la transmisión ... entorno totalmente seguro. Educación   "Imagine ...
(Date:5/24/2016)... , May 24, 2016  NxStage Medical, Inc. ... company focused on advancing renal care, today announced that ... to participate in the following schedule of investor conferences. ... made available at http://ir.nxstage.com/ .   ... Jefferies Healthcare Conference NY, NY           Friday, June 10, ...
(Date:5/24/2016)... 2016 Les ... la première endoprothèse à double thérapie au ... portant sur les membres inférieurs et la ... entreprise mondiale spécialisée dans la fourniture de ... a élargi son portefeuille pour inclure des ...
Breaking Medicine Technology: